1. Home
  2. AGIO vs NBTB Comparison

AGIO vs NBTB Comparison

Compare AGIO & NBTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • NBTB
  • Stock Information
  • Founded
  • AGIO 2007
  • NBTB 1856
  • Country
  • AGIO United States
  • NBTB United States
  • Employees
  • AGIO N/A
  • NBTB N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • NBTB Major Banks
  • Sector
  • AGIO Health Care
  • NBTB Finance
  • Exchange
  • AGIO Nasdaq
  • NBTB Nasdaq
  • Market Cap
  • AGIO 2.0B
  • NBTB 2.3B
  • IPO Year
  • AGIO 2013
  • NBTB N/A
  • Fundamental
  • Price
  • AGIO $30.28
  • NBTB $43.09
  • Analyst Decision
  • AGIO Buy
  • NBTB Hold
  • Analyst Count
  • AGIO 8
  • NBTB 3
  • Target Price
  • AGIO $56.57
  • NBTB $54.67
  • AVG Volume (30 Days)
  • AGIO 637.9K
  • NBTB 275.1K
  • Earning Date
  • AGIO 05-01-2025
  • NBTB 04-21-2025
  • Dividend Yield
  • AGIO N/A
  • NBTB 3.16%
  • EPS Growth
  • AGIO N/A
  • NBTB 12.07
  • EPS
  • AGIO 11.64
  • NBTB 2.97
  • Revenue
  • AGIO $36,498,000.00
  • NBTB $557,339,000.00
  • Revenue This Year
  • AGIO $50.61
  • NBTB $26.01
  • Revenue Next Year
  • AGIO $223.79
  • NBTB $12.39
  • P/E Ratio
  • AGIO $2.60
  • NBTB $14.51
  • Revenue Growth
  • AGIO 36.07
  • NBTB 13.66
  • 52 Week Low
  • AGIO $27.14
  • NBTB $32.93
  • 52 Week High
  • AGIO $62.58
  • NBTB $52.44
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 39.54
  • NBTB 37.59
  • Support Level
  • AGIO $30.00
  • NBTB $42.25
  • Resistance Level
  • AGIO $32.90
  • NBTB $44.67
  • Average True Range (ATR)
  • AGIO 1.22
  • NBTB 0.91
  • MACD
  • AGIO -0.08
  • NBTB 0.13
  • Stochastic Oscillator
  • AGIO 9.12
  • NBTB 34.98

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About NBTB NBT Bancorp Inc.

NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. NBT Bank is a full-service community bank offering a full range of retail and commercial banking products and trust and investment services. Loan products include consumer, home equity, mortgage, business banking, and commercial loans. Nearly half of its loan portfolio is in commercial loans. The bank serves individuals, corporations, and municipalities, and operates scores of locations throughout New York, Pennsylvania, Vermont, Massachusetts, New Hampshire, and Maine.

Share on Social Networks: